Keenova doses first patient in Phase 3 hammer toe drug trial

August 20, 2026 7:30 AM

Keenova Therapeutics plc announced that the first patient has been enrolled and dosed in its Phase 3 clinical trial evaluating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found